References
- Yu LX , LipkaE, CrisonJR, AmidonGL. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv. Drug Deliv. Rev.19, 359–376 (1996).
- Amidon GL , LennernasH, ShahVP, CrisonJR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res.12, 413–420 (1995).
- Oh DM , CurlRL, AmidonGL. Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model. Pharm. Res.10, 264–270 (1993).
- Yu LX , AmidonGL. A compartmental absorption and transit model for estimating oral drug absorption. Int. J. Pharm.186, 119–125 (1999).
- Bolger MB , LukacovaV, WoltoszWS. Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine. AAPS J.11, 353–363 (2009).
- Darwich AS , NeuhoffS, JameiM, Rostami-HodjeganA. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the “advanced dissolution, absorption, metabolism (ADAM)” model. Curr. Drug Metab.11, 716–729 (2010).
- Lukacova V , WoltoszWS, BolgerMB. Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release, and intravenous data. AAPS J.11, 323–334 (2009).
- Jamei M , TurnerD, YangJet al. Population-based mechanistic prediction of oral drug absorption. AAPS J. 11, 225–237 (2009).
- Huang W , LeeSL, YuLX. Mechanistic approaches to predicting oral drug absorption. AAPS J.11, 217–224 (2009).
- Yu LX , CrisonJR, AmidonGL. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int. J. Pharm.140, 111–118 (1996).
- Kuentz M . Drug absorption modeling as a tool to define the strategy in clinical formulation development. AAPS J.10, 473–479 (2008).
- Jones HM , ParrottN, OhlenbuschG, LaveT. Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling. Clin. Pharmacokinet.45, 1213–1226 (2006).
- Parrott N , LukacovaV, FraczkiewiczG, BolgerMB. Predicting pharmacokinetics of drugs using physiologically based modeling – application to food effects. AAPS J.11, 45–53 (2009).
- Shono Y , JantratidE, JanssenNet al. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling. Eur. J. Pharm. Biopharm. 73, 107–114 (2009).
- Woodcock J . The concept of pharmaceutical quality. Am. Pharm. Rev.1–3 (2004).
- Lionberger RA , LeeSL, LeeL, RawA, YuLX. Quality by design: concepts for ANDAs. AAPS J.10, 268–276 (2008).
- Yu LX . Pharmaceutical quality by design: product and process development, understanding, and control. Pharm. Res.25, 781–791 (2008).
- Jiang W , KimS, ZhangXet al. The role of predictive biopharmaceutical modeling and simulation in drug development and regulatory evaluation. Int. J. Pharm. 418, 151–160 (2011).
- Selen A , CruanesMT, MullertzAet al. Meeting report: applied biopharmaceutics and quality by design for dissolution/release specification setting: product quality for patient benefit. AAPS J. 12, 465–472 (2010).
- Zhang X , LionbergerRA, DavitBM, YuLX. Utility of physiologically based absorption modeling in implementing quality by design in drug development. AAPS J.13, 59–71 (2011).
- Short SM , CogdillRP, Drennen Iii JK, Anderson CA. Performance-based quality specifications: the relationship between process critical control parameters, critical quality attributes, and clinical performance. J. Pharm. Sci. (2010) (Epub ahead of print).
- Wei H , LobenbergR. Biorelevant dissolution media as a predictive tool for glyburide a class II drug. Eur. J. Pharm. Sci.29, 45–52 (2006).
- Okumu A , DiMasoM, LobenbergR. Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products. Eur. J. Pharm. Biopharm.72, 91–98 (2009).
- Schiller C , FrohlichCP, GiessmannTet al. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment Pharmacol. Ther. 22, 971–979 (2005).
- Jinno J , KamadaN, MiyakeMet al. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J. Control Release. 111, 56–64 (2006).